Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

J&J beats earnings estimates, posts weak medical device sales

Earnings report Spin-off AI-generated analysis

πŸ“‰ J&J's medical technology division reported Q3 sales of US$8.6 billion, missing analyst estimates of US$8.71 billion for the second consecutive quarter.

🌍 Geopolitical tensions in the Middle East and austerity in Europe weighed heavily on international device sales, with key markets like Saudi Arabia shifting budgets to defense.

πŸ’Š Pharmaceutical sales surged 7.7% to US$16.76 billion, driven by a 68% increase in Tremfya revenue which now largely replaces lost Stelara income.

πŸš€ The company raised its full-year adjusted earnings forecast midpoint to US$11.10 per share and total sales guidance to US$101.2 billion.

βš–οΈ J&J reaffirmed its plan to spin off the DePuy Synthes orthopedics unit by mid-2027 to sharpen focus on higher-growth healthcare segments.

πŸ“ˆ Total Q3 revenue of US$25.4 billion beat Wall Street estimates of US$25.28 billion, with adjusted earnings topping expectations by 5 cents.

Bullish Signals
  • J&J reported third-quarter total revenue of US$25.4 billion, beating analyst estimates of US$25.28 billion.
  • Pharmaceutical sales jumped 7.7% to US$16.76 billion, with Tremfya revenue rising 68% to US$2.4 billion and exceeding expectations.
  • The company raised its full-year adjusted earnings forecast midpoint to US$11.10 per share from the previous US$11.04.
  • J&J increased its full-year sales forecast to US$101.2 billion, indicating confidence in improving fourth-quarter performance.
  • Sales of Darzalex rose 16% to US$4.24 billion, demonstrating continued strength in the blood cancer treatment portfolio.
Risk Factors
  • Medical technology division sales fell short of estimates at US$8.6 billion against expectations of US$8.71 billion for the second straight quarter.
  • International device sales were flat outside the US due to geopolitical issues in the Middle East and austerity measures in Europe.
  • Pricing pressures in China continued to weigh on results, contributing to the underperformance in the medical devices segment.
  • Shares fell more than six percent following the earnings report as investors reacted to the weak medical device sales.
Full Analysis
Johnson & Johnson reported third-quarter results that beat Wall Street estimates on total revenue but missed expectations for its medical devices segment. The company posted quarterly revenue of US$25.4 billion, surpassing analyst estimates of US$25.28 billion, with adjusted earnings of US$2.59 per share topping expectations by 5 cents. However, the medical technology division specifically underperformed, recording sales of US$8.6 billion against an estimate of US$8.71 billion, marking the second consecutive quarter of misses for this unit. Chief Financial Officer Joe Wolk attributed the weakness in the medical devices business to geopolitical headwinds, particularly the Middle East conflict, as well as austerity measures in Europe and pricing pressures in China. While fuel costs have not yet impacted the company's bottom line, sales in key markets like Kuwait, UAE, and Saudi Arabia were hurt as these nations reallocated budgets toward defense spending rather than healthcare. The division saw a 2.5% overall rise to US$8.6 billion globally, but sales outside the United States remained essentially flat. Pharmaceutical sales provided a significant boost to the broader results, jumping 7.7% to US$16.76 billion driven by strong performance in autoimmune treatments like Tremfya and Darzalex. Despite facing generic competition that caused Stelara sales to fall 54%, the drug still exceeded diminished expectations. The company also reaffirmed its plan to spin off its orthopedics unit, DePuy Synthes, aiming for a mid-2027 separation to focus on higher-growth segments and create long-term value for shareholders. Analysts noted that J&J's specific disruptions from China supply chains and the pending spin-off make it difficult to generalize the medical device miss to the wider sector. While shares fell more than six percent following the report, the company raised its full-year sales forecast to US$101.2 billion and increased its adjusted earnings midpoint to US$11.10 per share, signaling confidence in improving fourth-quarter performance despite current headwinds.